112 SAFETY AND EFFICACY OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN THE TREATMENT OF ACUTE PHASE PEYRONIE’S DISEASE Nguyen, H.M.T. 1 ; Anaissie, J. 1 ; DeLay, K.J. 1 ; Yaﬁ, F.A. 2 ; Sikka, S.C. 1 ; Hellstrom, W.J. 1 1 Tulane University, USA; 2 University of California, Irvine, USA Objective: To examine the efﬁcacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of acute phase Peyronie’s Disease (PD). Material and Methods: We retrospectively reviewed the records for all patients treated with CCH for PD between 04/2014 and 09/2017. Patients who reported penile pain and duration of PD  12 months at presentation qualiﬁed as being in the acute phase of PD. The primary outcomes of interest were ﬁnal changes in curvature after CCH treatment regardless of number of CCH cycles received, and frequency of treatment-related adverse events (TRAE). Results: A total of 162 patients were included in the study, of which 36 (22%) qualiﬁed as acute phase PD (group 1) and the remaining 126 (78%) as stable phase (group 2). Median duration of PD was 8.5 (range: 1-12) months for group 1, and 18 (range: 1-492) months for group 2. There was no signiﬁcant difference in ﬁnal change in curvature between the acute and stable phase of PD (16.7vs. 15.6,p¼0.654). There was no statistically signiﬁ- cant difference in frequency of treatment-related adverse events between the acute phase (4 patients, 11%) and the stable phase (12 patients, 10%) (p¼0.778). Conclusions: Although CCH is currently not an indication during the acute phase of PD, preliminary results suggest that CCH use during this setting may be both effective and safe. There was no statistically signiﬁcant difference in ﬁnal change in curvature or treatment-related adverse events after CCH therapy delivered between the acute and stable phase of PD. Disclosure: Work supported by industry: no. The presenter or any of the authors act as a consultant, employee (part time or full time) or shareholder of an industry. 113 RACIAL VARIATIONS IN RESPONSE TO INTRALESIONAL COLLAGENASE CLOSTRIDIUM HISTOLYTICUM IN MEN WITH PEYRONIE’S DISEASE Nguyen, H.M.T. 1 ; DeLay, K.J. 1 ; Haney, N.M. 1 ; Anaissie, J. 1 ; Yaﬁ, F.A. 2 ; Hellstrom, W.J. 1 1 Tulane University, USA; 2 University of California, Irvine, USA Objective: To examine potential racial variations between Caucasian American (CA) and African American (AA) men in the efﬁcacy and safety of collagenase Clostridium histolyticum (CCH) in the treatment of Peyronie’s Disease (PD). Material and Methods: We retrospectively reviewed the records for all patients treated with CCH for PD between 04/2014 and 05/2017. Patients were divided into two groups based on their self-reported race. The primary outcomes of interest were ﬁnal change in curvature after CCH treatment regardless of number of CCH cycles received, and frequency of treatment-related adverse events. Results: A total of 159 patients were included in the study, of which 146 (91.8%) were CA while 13 (8.2%) were AA. Mean duration of PD was 28.3 months for CA patients and 16.8 months for CA patients (p¼0.436). There was no signiﬁcant difference in ﬁnal change in curvature CA and AA patients (15.9  vs. 13.1  respectively, p¼0.445). There was no statisti- cally signiﬁcant difference in frequency of treatment-related adverse events between CA patients (16, 11%) and AA patients (0, 0%) (p¼0.208). Conclusions: Although racial variations in efﬁcacy and safety of CCH in patients with PD have not been addressed in the literature, preliminary results from our study suggest that CCH therapy may be equally efﬁcacious and safe in both CA and AA men. There was no statistically signiﬁcant difference in ﬁnal change in curvature, International Index of Erectile Function scores, penile length, or treatment-related adverse events after CCH treatment between CA and AA patients. Disclosure: Work supported by industry: no. The presenter or any of the authors act as a consultant, employee (part time or full time) or shareholder of an industry. 114 EFFECT OF COLLAGENASE CLOSTRIDIUM HISTOLYTICUM ON PENILE VASCULAR AND MORPHOLOGICAL PARAMETERS IN PATIENTS WITH PEYRONIE’S DISEASE Diao, L. 1 ; Anaissie, J. 1 ; Nguyen, H.M.T. 1 ; Yaﬁ, F.A. 2 ; Haney, N. 1 ; DeLay, K.J. 1 ; Peak, T. 3 ; Sikka, S.C. 1 ; Hellstrom, W. 1 1 Tulane University, USA; 2 University of California, Irvine, USA; 3 Wake Forest Medical School, USA Objective: To examine the changes in penile vascular parameters after the administration of collagenase Clostridium Histolyticum (CCH) in patients with Peyronie’s disease (PD). Material and Methods: We retrospectively reviewed the records for all patients treated with CCH for PD between 04/2014 and 05/2017 who underwent penile duplex Doppler ultrasound (PDDU) after pharmacologically induced erection both before and after four cycles of CCH treatment. The primary outcomes measured were changes in peak systolic velocity (PSV), end diastolic velocity (EDV), and resistive index (RI) after CCH treatment. Paired t-Tests, chi-squared tests, and correlation co- efﬁcients were performed between functional and vascular pa- rameters before and after four rounds of CCH to determine statistical signiﬁcance (P<0.05). Results: A total of 51 patients were included in the study. After four cycles of CCH therapy, there was no statistically signiﬁcant change in PSV, EDV, RI, or International Index of Erectile Function score when compared to baseline. Similarly, there was no correlation between vascular parameters and change in J Sex Med 2018;15:S1eS93 18th Annual Fall Scientiﬁc Meeting of SMSNA S25 Downloaded from https://academic.oup.com/jsm/article/15/Supplement_1/S25/7011312 by guest on 02 February 2023